ARCHIVES

GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer.

This article is from The Cancer Letter archive.

Vol. 33 No. 40 | November 2, 2007

Download PDF Visit The Full Archive

Related Articles

HPV Vaccine Cervarix Active In 100% Of Women In Study

July 27, 2007

ImClone Protocol Generates More Questions Than Answers.

February 15, 2002

In Brief: Gramm-Rudman-Hollings Could Slash NCI Budget By $650 Million; Holleb Retires From ‘Ca’

July 27, 1990

Saffiotti Quits As Carcinogenesis Chief With Blast At Rauscher, Peters

April 30, 1976

Managed Care: Cancer Panel Finds Need “Critical” For Cost, Outcomes Data

September 13, 1996

The Lancet Oncology Issues “Expression Of Concern” Over Paper

July 23, 2010